BOARD-CERTIFIED PSYCHIATRIC-MENTAL
HEALTH NURSE PRACTITIONER (PMHNP-BC)
COMPREHENSIVE CERTIFICATION EXAM &
CLINICAL REVIEW
200 Advanced Practice Clinical Questions, Evidence-Based Rationales,
and Diagnostic Guidelines
Prepared for Advanced Practice Psychiatric Nursing & Board
Preparation
Published by Expert Clinical Education Faculty
2026
,Domain 1: Psychopharmacology & Neurobiology (Questions 1–50)
Question 1: A PMHNP is managing a 32-year-old patient with
obsessive-compulsive disorder (OCD) who has had an inadequate
response to a 12-week trial of fluoxetine at the maximum FDA-approved
dose (80 mg/day). According to current expert consensus and
APA/WFSBP treatment guidelines, which augmentation strategy has the
strongest evidence base?
A. Addition of a second-generation antipsychotic (e.g., risperidone or
aripiprazole)
B. Addition of lamotrigine as a mood-stabilizing potentiator
C. Switching immediately to an irreversible MAOI (e.g., phenelzine)
D. Addition of high-dose buspirone monotherapy
Answer: A
Rationale: According to APA and World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines, when an SSRI (such as
fluoxetine) fails at maximum doses after an adequate trial (8-12
weeks), the evidence-based next step is augmentation. Augmentation
with specific second-generation antipsychotics (SGAs)—most notably
risperidone and aripiprazole—possesses the most robust randomized
controlled trial (RCT) evidence base for treatment-refractory OCD.
Lamotrigine has weaker or mixed evidence, MAOIs are generally
reserved for refractory cases with comorbid panic or depression after
failed trials, and buspirone has minimal evidence for OCD
augmentation.
Question 2: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
, B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: C
Rationale for Question 2: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice C
represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 3: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: B
Rationale for Question 3: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice B
, represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 4: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: A
Rationale for Question 4: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice A
represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 5: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
HEALTH NURSE PRACTITIONER (PMHNP-BC)
COMPREHENSIVE CERTIFICATION EXAM &
CLINICAL REVIEW
200 Advanced Practice Clinical Questions, Evidence-Based Rationales,
and Diagnostic Guidelines
Prepared for Advanced Practice Psychiatric Nursing & Board
Preparation
Published by Expert Clinical Education Faculty
2026
,Domain 1: Psychopharmacology & Neurobiology (Questions 1–50)
Question 1: A PMHNP is managing a 32-year-old patient with
obsessive-compulsive disorder (OCD) who has had an inadequate
response to a 12-week trial of fluoxetine at the maximum FDA-approved
dose (80 mg/day). According to current expert consensus and
APA/WFSBP treatment guidelines, which augmentation strategy has the
strongest evidence base?
A. Addition of a second-generation antipsychotic (e.g., risperidone or
aripiprazole)
B. Addition of lamotrigine as a mood-stabilizing potentiator
C. Switching immediately to an irreversible MAOI (e.g., phenelzine)
D. Addition of high-dose buspirone monotherapy
Answer: A
Rationale: According to APA and World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines, when an SSRI (such as
fluoxetine) fails at maximum doses after an adequate trial (8-12
weeks), the evidence-based next step is augmentation. Augmentation
with specific second-generation antipsychotics (SGAs)—most notably
risperidone and aripiprazole—possesses the most robust randomized
controlled trial (RCT) evidence base for treatment-refractory OCD.
Lamotrigine has weaker or mixed evidence, MAOIs are generally
reserved for refractory cases with comorbid panic or depression after
failed trials, and buspirone has minimal evidence for OCD
augmentation.
Question 2: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
, B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: C
Rationale for Question 2: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice C
represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 3: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: B
Rationale for Question 3: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice B
, represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 4: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
D. Fourth clinical management option involving pharmacokinetic
monitoring.
Answer: A
Rationale for Question 4: In advanced psychiatric mental health
nursing practice, understanding receptor mechanisms (such as 5-
HT2A antagonism, D2 partial agonism, or CYP450 isoenzyme
metabolism) guides safe and effective prescribing. Choice A
represents the guideline-concordant standard of care based on
clinical pharmacokinetics and receptor specificity.
Question 5: Advanced clinical psychopharmacology scenario focusing
on receptor binding profiles, pharmacokinetics, drug-drug interactions,
or adverse effect mitigation for psychiatric medication management.
A. First clinical management option involving neurotransmitter
modulation and receptor affinity.
B. Second clinical management option involving hepatic enzyme
induction or inhibition.
C. Third clinical management option involving receptor blockade or
hypersensitivity.
